Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Cancer
Farshid Dayyani
Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Colon
Rectum

Study Description

This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

Eligibility

Subjects can participate in this study if they satisfy the following criteria:

  • At least 18 years of age
  • Confirmed diagnosis of adenocarcinoma (cancer) of the colon
  • Positive ctDNA assay (test)

Subjects cannot participate in this study if they have any of the following criteria:

  • Previous treatment with either irinotecan or TAS-102
  • Any active infection or other cancers
  • Pregnant or nursing
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.